NCT04830397 — "Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension)." trial site landscape

Public-registry site landscape for NCT04830397, “Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).”, a Primary Open Angle Glaucoma study sponsored by Qlaris Bio, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT04830397 (registry record)
Study title	Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
Official title	A Randomized Active-controlled Multi-site Double-masked Study to Evaluate the Safety and Tolerability of 3 Concentrations of QLS-101 Versus Timolol Maleate Preservative Free (PF) 0.5% Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Sponsor	Qlaris Bio, Inc.
Condition(s)	Primary Open Angle Glaucoma; Ocular Hypertension
Phase	PHASE2
Listed sites	1
Site countries	United States

Patient-friendly overview of this study: eichor.com/study/NCT04830397.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT04830397 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →